Exclusive Summary

• The originator's patent has expired with zero IP risk, offering a prime window to replace the aging supply chain of major pharmaceutical companies.
• Targeting the massive population with resistant hypertension and elderly patients with coexisting BPH, ensuring a rigid and growing global demand.
• The unique dual mechanism lowers blood pressure without inducing reflex tachycardia, while the sustained-release formulation significantly improves chronic compliance.
• Supported by ICH-compliant CTD dossiers and strict GMP manufacturing, enabling fast-tracked local registration for overseas distributors.
• Leveraging China's scaled manufacturing capabilities, it offers highly competitive pricing to generate substantial profit margins and secure tender wins.